Related Experiment Video
Updated: Jul 18, 2026
04:44
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
[Therapeutic management of systemic sclerosis]
Luc Mouthon1, Alice Berezné, Serge Poiraudeau
1Service de Médecine Interne, Hôpital Cochin, Centre de Référence pour les Vascularites Nécrosantes et la Sclérodermie Systémique, Assistance Publique-Hôpitaux de Paris, Université Paris-Descartes, Faculté de Médecine. luc.mouthon@cch.aphp.fr
Presse Medicale (Paris, France : 1983)
|December 13, 2006
Summary
Systemic sclerosis (SSc) treatment shows limited efficacy with current disease-modifying agents. New therapies, including cyclophosphamide (CYC) and organ-specific treatments, offer potential benefits for SSc patients.
Area of Science:
- Rheumatology
- Immunology
- Pulmonology
Background:
- Systemic sclerosis (SSc) pathophysiology is increasingly understood, yet effective disease-modifying treatments remain limited.
- Current treatments for SSc have not demonstrated improved survival in prospective randomized trials.
Purpose of the Study:
- To review current and emerging therapeutic strategies for systemic sclerosis.
- To highlight the limited efficacy of traditional antifibrotic agents and the potential of novel approaches.
Main Methods:
- Literature review of systemic sclerosis treatments.
- Analysis of clinical trial data and therapeutic outcomes.
Main Results:
- Traditional antifibrotic agents like colchicine and D-penicillamine show disappointing results.
- Cyclophosphamide (CYC) demonstrates benefit in SSc-associated interstitial lung disease.
- Organ-specific therapies (e.g., ACE inhibitors for renal failure, epoprostenol for pulmonary hypertension) offer significant benefits.
- Emerging therapies include high-dose CYC with stem cell transplantation, vasodilators, and anti-inflammatory/antifibrotic agents.
Conclusions:
- Novel therapeutic strategies are under investigation for systemic sclerosis.
- Physical therapy and rehabilitation are crucial for managing disability and functional loss in SSc patients.
Related Concept Videos
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:20Rheumatic Heart Disease IV: Nursing Management
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...